Biomaterials-based in situ tissue engineering
Graphical abstract
Section snippets
Biomaterials for in situ tissue engineering
Materials suitable for in situ tissue engineering (TE) include those that are either synthetic or naturally occurring in composition. However, such materials must possess the following two properties: be degradable, and elicit either a minimal pro-inflammatory response or an anti-inflammatory, immunomodulatory response. The formation of new, site-appropriate tissue that at least partially restores structure and function to the injured or missing anatomy implies circumvention of the default
Synthetic biomaterials
Synthetic biomaterials are commonly used in the practice of medicine and are manufactured from a variety of base materials such as stainless steel, polypropylene, silicone, and polyurethanes, among others 1, 2, 3, 4. Synthetic biomaterials can be manufactured with high precision and can be terminally sterilized and packaged by well-recognized and accepted methods. Some synthetic materials are degradable within the human body (e.g., polylactic-glycolic acid) while others are essentially
Naturally occurring materials
Materials composed of the secreted products of cells, including the extracellular matrix (ECM) or individual components of ECM such as collagen, are considered to be naturally occurring materials. For example, ECM bioscaffold materials composed of urinary bladder matrix (UBM) and small intestinal submucosa (SIS) are manufactured by the decellularization of their source tissue. These materials often retain sufficient bioactivity to promote positive remodeling effects such as
Hybrid biomaterial approaches
To capitalize upon the positive features of both synthetic and biologic materials, hybrids have been used for in situ use. For example, the strength and architectural versatility of synthetic scaffolds can be combined with the bioactive signals and biocompatibility of natural scaffold materials. Photo-crosslinkable methacrylated chondroitin sulphate and adipose-derived stem cells were used with or without decellularized adipose tissue in hydrogel form as a minimally invasive in situ approach to
Conclusion
Limitations in the understanding of biologic events that are required for normal tissue in organ development hinder the successful clinical translation of tissue engineering approaches that require extensive ex vivo bioreactor time. By using the body as a bioreactor, one can capitalize upon the natural in vivo microenvironment as an alternative TE approach; i.e., in situ TE. Biomaterials that can provide a favorable microenvironment for in situ TE include synthetic, biologic and hybrid
Acknowledgements
Mark Murdock is supported by the National Institutes of Health (NIH) Clinical and Translational Science (CTS) Fellowship program [grant number 1 TL1 TR 1858-1]. This CTS TL1 award had no role in the writing of this review or the decision to submit the article for publication.
References (24)
- et al.
Mechanical properties of silicone elastomer on temperature in biomaterial application
Mater. Lett.
(2005) - et al.
Experimental tracheal replacement using tissue-engineered cartilage
J. Pediatr. Surg.
(1994) - et al.
Engineering of human tracheal tissue with collagen-enforced poly-lactic-glycolic acid non-woven mesh: a preliminary study in nude mice
Br. J. Oral Maxillofac. Surg.
(2007) - et al.
Curcumin loaded nano graphene oxide reinforced fish scale collagen – a 3D scaffold biomaterial for wound healing applications
Rsc Adv.
(2015) - et al.
Preparation and microstructure of HA-316L stainless steel fibre asymmetrical functionally graded biomaterial
J. Inorg. Mater.
(2005) - et al.
Springy polypropylene – novel elastomeric biomaterial
Int. J. Polym. Mater.
(1977) - et al.
A facile approach to modify polyurethane surfaces for biomaterial applications
Macromol. Biosci.
(2009) - et al.
In situ tissue engineering of functional small-diameter blood vessels by host circulating cells only
Tissue Eng. Part A
(2015) - et al.
Transplantation of chondrocytes utilizing a polymer-cell construct to produce tissue-engineered cartilage in the shape of a human ear
Plast. Reconstr. Surg.
(1997) - et al.
Generating ears from cultured autologous auricular chondrocytes by using two-stage implantation in treatment of microtia
Plast. Reconstr. Surg.
(2009)
A composite tissue-engineered trachea using sheep nasal chondrocyte and epithelial cells
Faseb J.
Tissue engineered cartilage generated from human trachea using DegraPol (R) scaffold
Eur. J. Cardiothorac. Surg.
Cited by (32)
Minimally invasive bioprinting for in situ liver regeneration
2023, Bioactive MaterialsIn-situ bioprinting of skin - A review
2023, BioprintingFunction-oriented design: A novel strategy for advanced biomedical materials
2023, Journal of Materials Science and TechnologyOmics-based approaches to guide the design of biomaterials
2023, Materials TodayRecent advances in bioprinting technologies for engineering different cartilage-based tissues
2021, Materials Science and Engineering CCitation Excerpt :The main objective of this approach is to repair the defective tissues – which generally involve curved surfaces and complex geometries - and overcome the limitations of conventional bioprinting techniques that are typically restricted to the generation of flat substrates [142,143]. This approach avoids the laborious preparation of the in vitro scaffold and the issues associated with contamination and the use of an inadequate in vitro cell culturing system [144]. Nevertheless, printing tissues directly in situ within operating rooms still represents a big challenge at different levels, ranging from the simple operating room organization to the maintenance of safety and sterility standards required for the procedure itself.
Urogynecological surgical mesh implants: New trends in materials, manufacturing and therapeutic approaches
2020, International Journal of PharmaceuticsCitation Excerpt :This challenging and new 3D bioprinting approach allows direct printing of bioinks to create or repair living tissues or organs at a defect site in a clinical setting (Guillemot et al., 2010; Singh et al., 2020), and therefore overcome some of the bioprinting of in vitro 3D scaffolds intrinsic limitations. These limitations include: the establishment of a bioreactor for the replacement with damaged tissue or organ (Murdock and Badylak, 2017; Wang et al., 2015), the implantation of the 3D construct (a fragile structure) in the body, and the shape or morphology of the developed construct, which may differ from the actual defect size due to the limited resolution of the current imaging techniques, such as of computed tomography (CT) and magnetic resonance imaging (MRI) scans (Singh et al., 2020). Although the use of this novel technique is currently considered challenging owing to the lack of skill set required, some previous investigations have already shown the potential of this approach for tissue engineering (Di Bella et al., 2018; Li et al., 2017; Singh et al., 2020).